Follow these drug-billing tips to lower your J-code denial rate, reduce audits
In the latest reminder that even the tiniest details of your claims can get you audited, a nationwide dialysis provider, U.S. Renal Care, recently paid $7.3 million to resolve a whistleblower lawsuit that alleged a pattern of overbilling for the anti-anemia drug Epogen (J0886).
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.